Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Stomach Neoplasms 6Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Squamous-Cell Non-Small-Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1GastroEsophageal Cancer 1Gastric or Gastroesophageal Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma of Lung 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 30Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Radiotherapy 16Pemetrexed 15Albumin-Bound Paclitaxel 15Nivolumab 13Ramucirumab 11Cyclophosphamide 11Drug Therapy 9Trastuzumab 8Erlotinib Hydrochloride 8zolbetuximab 7Taxes 7Radiosurgery 7trastuzumab deruxtecan 6cemiplimab 6Blood Specimen Collection 6regorafenib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma × bemarituzumab × Clear all
NCT06967987 2026-01-21

BEMAFLOT

Institut Cancerologie de l'Ouest

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma

NCT02213289 2021-04-08

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

University of Chicago

Phase 2 Completed
80 enrolled 14 charts
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡